Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04215731 | Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer(FOBEAR) | recruiting | Phase 3 | 582 | Yanhong DengOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04928807 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) | active not recruiting | Phase 3 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Feb 27, 2026 |
| clinicaltrials |
| NCT04428905 | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | active not recruiting | Phase 3 | 403 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 446 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02956876 | Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer(INCISIVE) | completed | Phase 3 | 207 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00208260 | Intensified Chemotherapy in CRC After Resection of Liver Metastases | completed | Phase 2 / Phase 3 | 124 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM) | recruiting | Phase 3 | 480 | University of Campania Luigi VanvitelliOTHER | 2 | Feb 5, 2026 | clinicaltrials |
| NCT07384377 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | not yet recruiting | Phase 3 | 123 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Feb 3, 2026 | clinicaltrials |
| NCT02448173 | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | not yet recruiting | Phase 3 | 550 | Vaccinogen IncINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04495088 | Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 3 | 550 | Ralf HofheinzOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04854668 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 748 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07372300 | Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer(mEHT) | recruiting | Phase 3 | 126 | Shih-Kai HungOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 220 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 26, 2026 | clinicaltrials |
| NCT07362836 | Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) | not yet recruiting | Phase 3 | 224 | Fudan UniversityOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07361003 | A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | recruiting | Phase 3 | 464 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03875781 | Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer(NORAD01) | recruiting | Phase 3 | 540 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04095299 | Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients(WW3) | recruiting | Phase 3 | 162 | Vejle HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07320950 | Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients | completed | Phase 3 | 333 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07309289 | NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | recruiting | Phase 3 | 144 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06791512 | mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC(BASKETⅢ) | recruiting | Phase 3 | 166 | Jun HuangOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06686576 | A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 363 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05008809 | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | recruiting | Phase 3 | 507 | Dominik Paul ModestOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06733038 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.(AtezoTRIBE2) | recruiting | Phase 3 | 238 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05600309 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | completed | Phase 3 | 94 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03829462 | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients(NEXT-REGIRI) | active not recruiting | Phase 3 | 377 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06940947 | Endoscopic Therapy Or Surgery for Early Colon Cancer(ETHOS) | recruiting | Phase 3 | 434 | Norwegian Department of Health and Social AffairsOTHER_GOV | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting(IROCAS) | completed | Phase 3 | 792 | UNICANCEROTHER | 2 | Nov 17, 2025 | clinicaltrials |
| NCT01999634 | Monitoring by Microdialysis of Postoperative Complications After Proctectomy(MTM-COLON-II) | completed | Phase 3 | 21 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01727388 | Informativeness to Digital Rectal Examination(RIFIONA) | completed | Phase 3 | 320 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06490536 | The Sagittarius Trial | recruiting | Phase 3 | 700 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT02605265 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1(CinClare) | completed | Phase 3 | 356 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04941300 | ColoRectal Cancer Screening for Southern California Community Health Centers | completed | Phase 3 | 55,999 | University of California, San DiegoOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 252 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06839092 | Prophylactic PIPAC in Patients With High-risk Colorectal Cancer(PROPAC) | not yet recruiting | Phase 3 | 160 | Jeremy MeyerOTHER | 0 | Jul 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2026source: clinicaltrials